[{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"La Jolla Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"La Jolla Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Pharma Group","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shanghai Pharma Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Pharma Group \/ Everest Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Pharma Group \/ Everest Medicines"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ AcelRx Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ AcelRx Pharmaceuticals"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Armistice Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ Armistice Capital","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ Armistice Capital"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"TTY BIOPHARM CO LTD","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ TTY BIOPHARM CO LTD","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ TTY BIOPHARM CO LTD"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Ewha Womans University","sponsor":"SOM Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ewha Womans University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ewha Womans University \/ SOM Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Ewha Womans University \/ SOM Biotech"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SOM Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SOM Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SOM Biotech \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Eravacycline

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

MAGHREB PHARMA
Not Confirmed
MAGHREB PHARMA
Not Confirmed

Details : Xerava (eravacycline) is a novel, fully synthetic, fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant ("MDR") isolates.

Product Name : Xerava

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

September 27, 2023

Lead Product(s) : Eravacycline

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

02

MAGHREB PHARMA
Not Confirmed
MAGHREB PHARMA
Not Confirmed

Details : XERAVA® (eravacycline) is a novel, fully synthetic, fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant ("MDR") isolates.

Product Name : Xerava

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 27, 2023

Lead Product(s) : Eravacycline

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

03

MAGHREB PHARMA
Not Confirmed
MAGHREB PHARMA
Not Confirmed

Details : Under the partnership, Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA (eravacycline), a novel, fully synthetic, fluorocycline intravenous antibiotic, in China.

Product Name : Xerava

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

April 18, 2023

Lead Product(s) : Eravacycline

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Sponsor : Everest Medicines

Deal Size : Undisclosed

Deal Type : Partnership

blank

04

MAGHREB PHARMA
Not Confirmed
MAGHREB PHARMA
Not Confirmed

Details : Xerava (eravacycline) is bacteriostatic which disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit thus preventing the incorporation of amino acid residues into elongating peptide chains.

Product Name : Xerava

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 16, 2023

Lead Product(s) : Eravacycline

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

05

MAGHREB PHARMA
Not Confirmed
MAGHREB PHARMA
Not Confirmed

Details : Xerava™ (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired multidrug res...

Product Name : Xerava

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

November 08, 2022

Lead Product(s) : Eravacycline

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Sponsor : TTY BIOPHARM CO LTD

Deal Size : Undisclosed

Deal Type : Partnership

blank

06

World Vaccine Conference
Not Confirmed
World Vaccine Conference
Not Confirmed

Details : XERAVA® (eravacycline) for injection is approved by the U.S. Food and Drug Administration (FDA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older.

Product Name : Xerava

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 14, 2022

Lead Product(s) : Eravacycline

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

07

MAGHREB PHARMA
Not Confirmed
MAGHREB PHARMA
Not Confirmed

Details : XERAVA® (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired MDR and are pr...

Product Name : Xerava

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 10, 2022

Lead Product(s) : Eravacycline

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

08

MAGHREB PHARMA
Not Confirmed
MAGHREB PHARMA
Not Confirmed

Details : Xerava (eravacycline) is a novel, fully synthetic, broad-spectrum parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired multidrug resistance (MDR) and a...

Product Name : Xerava

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 08, 2021

Lead Product(s) : Eravacycline

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

09

MAGHREB PHARMA
Not Confirmed
MAGHREB PHARMA
Not Confirmed

Details : In vitro experiments confirmed inhibition of the protease with an IC50 in the low micromolar range. Eravacycline inhibits the infection of SARS-CoV-2 in VeroE6 cells and shows no toxicity when applied alone.

Product Name : TP-434

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 19, 2020

Lead Product(s) : Eravacycline

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Preclinical

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

10

MAGHREB PHARMA
Not Confirmed
MAGHREB PHARMA
Not Confirmed

Details : Through this acquisition, Melinta will enhance its commercial portfolio with XERAVATM. Once the transaction closes, Melinta will have a portfolio of five complementary marketed antibiotics: VABOMERE, ORBACTIV, BAXDELA, MINOCIN for Injection, and XERAVATM...

Product Name : Xerava

Product Type : Other Small Molecule

Upfront Cash : $55.0 million

September 06, 2020

Lead Product(s) : Eravacycline

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Sponsor : Melinta Therapeutics

Deal Size : $55.0 million

Deal Type : Merger

blank